Outset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S.
April 17 2024 - 8:30AM
Business Wire
Agreement designed to provide patients and
caregivers access to innovative home dialysis with the Tablo®
Hemodialysis System
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical
technology company pioneering a first-of-its-kind technology to
reduce the cost and complexity of dialysis, and U.S. Renal Care,
the largest privately held kidney care provider in the United
States, announced today a multi-year agreement to help accelerate
home hemodialysis in the U.S.
Studies show patients with end-stage kidney disease (ESKD) are
healthier mentally and physically dialyzing at home, more likely to
be employed and maintain more control of their daily activities.
Yet, just 3% of the ESKD population currently performs home
hemodialysis, in large part due to historically complicated systems
that made it too difficult to undertake or sustain. Under the
multi-year agreement, U.S. Renal Care can utilize Outset’s Tablo
Hemodialysis System as a home dialysis option throughout the 33
states in which it provides care. Patients dialyzing with Tablo
report that the system is easy to learn and operate in their home.
Expanding treatment options in the communities served by U.S. Renal
Care will aid in meeting the growing demand of dialysis patients
seeking treatment at home.
"Our collaboration with U.S Renal Care is an important step
forward in providing dialysis patients with options for where, when
and how they want to dialyze.” said Leslie Trigg, Chair and CEO of
Outset Medical. “Tablo was specifically designed to reduce the
complexity of dialysis and help restore the identity and agency of
patients who must dialyze to survive. We are pleased to partner
with U.S. Renal Care to advance this mission.”
“We strive to provide patients with new and innovative solutions
that deliver the best outcomes possible,” said Steve Nottingham,
Co-Chief Operating Officer at U.S. Renal Care. “We have seen
success using the Tablo system in our home hemodialysis program,
and with our multi-year agreement with Outset, can continue
providing our patients and caregivers access to lifesaving dialysis
treatment in an easy-to-operate system, all in the comfort of their
own homes.”
Tablo, is indicated for use from the hospital to the home,
represents a significant technological advancement that transforms
the dialysis experience for patients and operationally simplifies
it for providers. Requiring just access to tap water and a standard
electrical outlet, Tablo serves as a single enterprise solution
that can be utilized across the continuum of care, allowing
dialysis to be delivered anytime, anywhere and by anyone.
About U.S. Renal Care
U.S. Renal Care, the largest privately held and fastest-growing
dialysis provider in the U.S., partners with nephrologists across
500 centers in 33 states to care for thousands of people living
with kidney disease nationwide. Since 2000, U.S. Renal Care has
been a leader in clinical quality, innovation, and operational
excellence – delivering the best experience and outcomes for our
patients.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a
first-of-its-kind technology to reduce the cost and complexity of
dialysis. The Tablo Hemodialysis System, FDA cleared for use from
the hospital to the home, represents a significant technological
advancement that transforms the dialysis experience for patients
and operationally simplifies it for providers. Tablo serves as a
single enterprise solution that can be utilized across the
continuum of care, allowing dialysis to be delivered anytime,
anywhere and by anyone. The integration of water purification and
on-demand dialysate production enables Tablo to serve as a dialysis
clinic on wheels, with 2-way wireless data transmission and a
proprietary data analytics platform powering a new holistic
approach to dialysis care. Tablo is a registered trademark of
Outset Medical, Inc.
Forward-Looking Statements
This press release may contain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements include statements regarding Outset’s
strategy, expectations, plans and prospects with respect to its
agreement with U.S. Renal Care, including the anticipated outcome
and benefits of the agreement. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified, which could cause actual results and
other events to differ materially from those expressed or implied
in such statements. These risks and uncertainties include risks
described in the Risk Factors section of Outset’s public filings
with the U.S. Securities and Exchange Commission, including its
latest annual and quarterly reports. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Outset disclaims any obligation to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240417356548/en/
Investor Contact Jim Mazzola 858-342-8272
jmazzola@outsetmedical.com
Media Contacts Jennifer Sipple
media@outsetmedical.com
U.S. Renal Care Press Press@USRenalCare.com
Outset Medical (NASDAQ:OM)
Historical Stock Chart
From Apr 2024 to May 2024
Outset Medical (NASDAQ:OM)
Historical Stock Chart
From May 2023 to May 2024